Lyell Immunopharma在欧洲血液学协会2026年大会上，公布了其候选疗法Rondecabtagene Autoleucel（Ronde-Cel）用于大B细胞淋巴瘤患者的最新安全数据与转化研究成果。此次披露的信息为这一细胞疗法的临床进展提供了关键更新。
该公司展示的数据聚焦于疗法的安全性特征以及从实验室到临床的深入洞见。这些发现有助于进一步评估Ronde-Cel在应对这一侵袭性淋巴瘤方面的潜力与风险平衡。
大会上的报告为医学界提供了关于该疗法最新进展的重要参考。相关数据的公布是Lyell Immunopharma推进其研发管线过程中的一个环节。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.